[Peri-operative use of EPO].
In moderately anaemic patients, Autologous Blood Donation is much less effective than Erythropoïetin (EPO) at constituting a pre-operative RBC reserve. Indeed, the ability to give blood is limited or even impossible for anaemic individuals. EPO lowers the risks associated with autologous and allogeneic transfusions, while improving probably the quality of life of the patients. EPO therapy is efficient, in moderate anaemic patients, to reduce allogeneic transfusion when iron supplementation is associated. All blood conservation techniques carry their own efficiency limits, constraints and risks that, in addition to institutional considerations and individual patient characteristics, are determinant to settle a blood conservation strategy. But to optimise benefit/cost/effectiveness of this technique, it is important to take into account the delay before surgery, the anticipated blood loss for the procedure that varies among institutions and the tolerable blood loss without transfusion for the patient. To reduce the cost, a strategy according to baseline haematocrit and to blood loss has to be adapted at each patient. Furthermore, when the delay between the first EPO injection and the surgical procedure is sufficient, the number of injections can be easily reduced to obtain the same Ht the day prior to surgery.
Rosencher
N
N
Service d'anesthésie-réanimation, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014, Paris, France. nadia.rosencher@cch.ap-hop-paris.fr <nadia.rosencher@cch.ap-hop-paris.fr>
Ozier
Y
Y
D000740:Anemia / Q000188:drug therapy; D001804:Blood Transfusion, Autologous / Q000009:adverse effects; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007430:Intraoperative Care; D011994:Recombinant Proteins; D012449:Safety; D065227:Transfusion Reaction; D014184:Transplantation, Homologous
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin